Human Data Can’t Wait for Clinical Trials.
3D HUMAN BIOLOGY-ON-A-CHIP FOR Humanized Drug Discovery and Diagnostic Applications
Accelerating drug discovery with AIM Biotech’s humanized BioAvatar products & services.
From the most demanding basic research, to predictive screens for drug discovery, to the tailored selection of precision medicines, AIM Biotech enables and accelerates the development of cutting-edge therapeutics. This is made possible through AIM Biotech’s BioAvatar technology, which embodies our core expertise in the design and manufacture of sophisticated microfluidic systems and human tissue models. Our BioAvatars combine unmatched recapitulation of human biology with unparalleled ease-of-use, resulting in a powerful solution to move medicine forward.
Humanized pre-clinical insights for increased predictability of clinical outcomes
Acceleration of the drug discovery process through easy-to-implement humanized organ-on-a-chip models
Replacement of animal models in pre-clinical trials
Human biology-on-a-chip. Simplified.
AIM Biotech’s proven 3D Cell Culture Chip, DAX-1
This is AIM Biotech’s proven 3D Cell Culture Chip, now part of the idenTx family. Designed in a microscope slide format, this most basic component of the idenTx family enables 3 simultaneous experiments. It is ideal for establishing experimental feasibility or for general low-throughput applications.
Human biology-on-a-chip. Standardized.
idenTx 9 Plate
Three fully integrated idenTx 3 Chips enable 9 simultaneous experiments; scale up for introduction of plate-based robotics and automation.
Human biology-on-a-chip. Multiplied.
idenTx 40 Plate
Highest-throughput plate option, enabling 40 simultaneous experiments to fully accelerate drug discovery through high-content screening.
Human Data. Experimental Simplicity.
Scalability without Compromise.
Unmatched ease-of-use: no special handling, no special training, no special hardware
Built in Scalability to take your research from feasibility to higher throughput screening
Your study. Our lab. Human data.
Contract research services for humanized, organ-on-a-chip studies
With AIM Biotech contract research services, increasing throughput while maintaining assay sophistication is our expertise. Our pharma-focused solutions combine speed and simplicity with the ability to model complex tissues that you expect from organ-on-a-chip assays.
Let AIM Biotech accelerate your drug discovery programs using our humanized BioAvatar Technology in our state-of-the-art research services lab. Our team can even work with you to design, develop, and execute custom assays to deliver human-focused, clinically-relevant results that move your drug discovery programs forward.
Custom assay development
Rapid humanized throughput
Functional immuno-oncology assays
Answer primary research questions
Data on routine screens
In-vitro organ models
Run simple assays or create complex biological models
T Cell Efficiency Assay
Blood Brain Barrier
Immunotherapy month: T-cells and transplants—avoiding cancer relapse after liver transplantation using AIM Biotech’s organ-on-a-chip assays
To round out our month-long series highlighting research on adoptive T cell immunotherapy, today we’ll take a look at how scientists are modifying T cells to help prevent cancer relapse on liver transplanted patients, harnessing AIM Biotech’s technology. In cases where a liver tumor can’t be...
Immunotherapy month: Receptor conflict—keeping cancer-killing T cells on-target using AIM Biotech’s organ-on-a-chip assays
This month on AIM’s Voices feed is dedicated to the fascinating research being done on adoptive T cell immunotherapy. Today, we’ll take a look at how scientists used AIM Biotech’s organ-on-a-chip technology to build on previous studies and refine this promising new technique to potentially...
Immunotherapy month: The immune system workaround—suppressing immune checkpoint expression to attack tumors with T cells in AIM Biotech’s organ-on-a-chip
You learned last week how AIM Biotech’s organ-on-a-chip is the perfect model for studying T cell migration to a 3D tumor while examining adoptive T cell immunotherapy. Today, we’ll discuss how scientists used the same technology to discover a major improvement to the therapy. A new obstacle:...